Repaglinide
Other Blood Glucose Lowering Drugs, Excl. Insulins
Sold as Enyglid · Prandin · NovoNorm
- Drug class
- Other Blood Glucose Lowering Drugs, Excl. Insulins
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 35
Overview
Repaglinide is an active pharmaceutical ingredient in the Other Blood Glucose Lowering Drugs, Excl. Insulins group (A10BX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 17 | April 17, 2026 |
| CA Canada | Health Canada | 12 | March 22, 2025 |
| EU European Union | EMA | 6 | February 11, 2025 |
GBUnited Kingdom· MHRA
17 products
Uses
Repaglinide is indicated in adults with type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes patients who are not satisfactorily controlled on metformin alone.
Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
How to take
CACanada· Health Canada
12 products
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS .................................................................................................
10 DOSAGE AND ADMINISTRATION ............................................................................. 15 OVERDOSAGE................................................................................................................
16 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 16 STORAGE AND STABILITY ......................................................................................... 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................
EUEuropean Union· EMA
6 products
Uses
Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.
Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
How to take
Drug interactions
Known interactions involving Repaglinide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 538. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL331550007 · revised October 11, 2024
- [2]Health Canada (DPD) · 02354926 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/001067 · revised February 11, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.